Premium
High glucose treatment enhances autotaxin and VEGF‐C expression in PC‐3 human prostate cancer cell (693.20)
Author(s) -
Lin ChuCheng,
Lee Hsinyu
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.693.20
Subject(s) - lysophosphatidic acid , autotaxin , prostate cancer , cancer research , lymphangiogenesis , cancer cell , metastasis , cancer , chemistry , prostate , vascular endothelial growth factor , cell growth , medicine , endocrinology , biology , biochemistry , vegf receptors , receptor
Clinical evidences suggest that lymphangiogenesis and lymphatic metastasis are important processes during the progression of prostate cancer. Vascular endothelial growth factor (VEGF)‐C was shown to be a key regulator in these processes. Our previous studies demonstrated that lysophosphatidic acid (LPA), a low‐molecular‐weight lipid growth factor, enhances VEGF‐C expression in three different human prostate cancer cell lines. In PC‐3 human prostate cancer cells, the enhancement effects of LPA were mediated through LPA 1/3 ‐, PLC‐, PKC‐, Nox‐, ROS‐, and LEDGF‐dependent pathways. Furthermore, autotaxin (ATX), an enzyme responsible for LPA synthesis, also participates in regulating VEGF‐C expression. Herein, we further demonstrated that the mRNA levels of ATX and VEGF‐C were increased in PC‐3 cell by 0.02 M of high glucose treatments within 2 hours. These processes can be suppressed by pretreatment with ROS scavenger, N‐acetylcysteine. These results suggested that the unregulated glucose metabolic conditions might lead to LPA synthesis and therefore the subsequent pathological conditions of prostate cancer. These novel findings could potentially provide new strategies for prostate cancer treatments.